




8:25AM	INTRODUCTION	
8:30AM	4DMEDICAL (4DX)	
9:00AM	NANOSONICS (NAN)	ion 1
9:30AM	POLYNOVO (PNV)	Session
10:00AM	AROA BIOSURGERY (ARX)	
10:25AM	MORNING TEA	
10:30AM	GENETIC SIGNATURES (GSS)	
11:00AM	INOVIQ (IIQ)	ion 2
11:30AM	CLINUVEL PHARMACEUTICALS (CUV)	Session
12:00PM	MICROBA LIFE SCIENCES (MAP)	
12:30PM	LUNCH	
1:00PM	NOVA EYE MEDICAL (EYE)	
1:30PM	ONEVIEW HEALTHCARE (ONE)	ion 3
2:00PM	AUSTCO HEALTHCARE (AHC)	Sess
2:30PM	TRAJAN (TRJ)	
2:55PM	AFTERNOON TEA	
3:00PM	ALCIDION (ALC)	
3:30PM	PHARMX TECHNOLOGIES (PHX)	Session 4
4:00PM	MACH7 TECHNOLOGIES (M7T)	Sess
4:30PM	PRO MEDICUS (PME)	
4:55PM	WRAP-UP	



8:25AM	INTRODUCTION	
8:30AM	IMPEDIMED (IPD)	
9:00AM	LTR PHARMA (LTP)	ion 1
9:30AM	MEDICAL DEVELOPMENTS (MVP)	Session
10:00AM	BIOME (BIO)	
10:25AM	MORNING TEA	
10:30AM	RADIOPHARM THERANOSTICS (RAD)	
11:00AM	CYCLOPHARM (CYC)	ion 2
11:30AM	CLARITY PHARMACEUTICALS (CU6)	Session 2
12:00PM	TELIX PHARMACEUTICALS (TLX)	
12:30PM	LUNCH	
1:00PM	ACTINOGEN MEDICAL (ACW)	
1:30PM	ALTERITY THERAPEUTICS (ATH)	ssion 3
2:00PM	AMPLIA THERAPEUTICS (ATX)	Sessi
2:30PM	IMUGENE (IMU)	
2:55PM	AFTERNOON TEA	
3:00PM	EBR SYSTEMS (EBR)	
3:30PM	EMVISION MEDICAL DEVICES (EMV)	ion 4
4:00PM	ANTERIS TECHNOLOGIES (AVR)	Session 4
4:30PM	IMRICOR MEDICAL SYSTEMS (IMR)	
4:55PM	WRAP-UP	



8:25AM	INTRODUCTION	
8:30AM	SYNTARA (SNT)	
9:00AM	IMMUTEP (IMM)	ion 1
9:30AM	IMMVIRX	Session
10:00AM	MESOBLAST (MSB)	
10:25AM	MORNING TEA	
10:30AM	SALUDA MEDICAL	
11:00AM	CYNATA THERAPEUTICS (CYP)	ion 2
11:30AM	POLYACTIVA	Session
12:00PM	ORTHOCELL (OCC)	
12:30PM	LUNCH	
1:00PM	PROTEOMICS (PIQ)	
1:30PM	VITRAFY LIFE SCIENCES (VFY)	ion 3
2:00PM	QBIOTICS	Sess
2:30PM	ARTRYA (AYA)	
2:55PM	AFTERNOON TEA	
3:00PM	ONCOSIL MEDICAL (OSL)	
3:30PM	PYC THERAPEUTICS (PYC)	Session 4
4:00PM	PARADIGM BIOPHARMACEUTICALS (PAR)	Sess
4:30PM	STARPHARMA (SPL)	
4:55PM	WRAP-UP	



8:30AM 4DMEDICAL (4DX)

4DMedical is a global MedTech company advancing respiratory care with Al-driven imaging. Its portfolio includes FDA-cleared XV LVAS® and CT LVAS™, anchored by CT:VQ™—a ground-breaking, noncontrast ventilation and perfusion solution redefining cardiothoracic imaging. Delivered via SaaS, 4DMedical empowers earlier diagnosis, precision treatment, and improved patient outcomes.

Market cap \$840.8M

9:00AM NANOSONICS (NAN)

Nanosonics is a global infection prevention company headquartered in Sydney, Australia. It designs, manufactures and distributes innovative automated disinfection technologies, including its flagship Trophon system for high-level disinfection of ultrasound probes. Nanosonics partners with major healthcare providers worldwide to improve patient safety and reduce hospital-acquired infection risks.

Market cap \$1.3B

9:30AM POLYNOVO (PNV)


PolyNovo is an Australian medical technology company specialising in advanced wound care and reconstructive solutions. Its proprietary NovoSorb biodegradable polymer platform is used in products like NovoSorb BTM to aid skin regeneration after burns, trauma, and surgery. PolyNovo markets globally, improving outcomes for patients with complex wounds.

Market cap \$853.2M

10:00AM AROA BIOSURGERY (ARX)

Aroa Biosurgery is a high-growth medical technology company based in New Zealand. It develops, manufactures and sells innovative soft-tissue repair and wound-healing devices using its proprietary extracellular matrix (ECM) technology. Aroa's products are marketed globally, improving surgical outcomes and supporting regenerative healing across diverse clinical applications.

Market cap \$264.0M



10:30AM GENETIC SIGNATURES (GSS)

Genetic Signatures is a molecular diagnostics company developing innovation infectious disease testing solutions. Its 3base technology powers the EasyScreen real-time PCR platform, enabling rapid, accurate detection of multiple pathogens from a single sample. The company focuses on advancing global diagnostic efficiency across clinical and public health settings.

Market cap \$63.6M

11:00AM INOVIQ (IIQ)

INOVIQ is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. Our product portfolio spans commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical-stage CAR-exosome therapeutic program targeting solid tumours.

Market cap \$48.6M

11:30AM CLINUVEL PHARMACEUTICALS (CUV)


Clinvuel Pharmaceuticals is a global specialty biopharmaceutical company developing and commercialising therapies for genetic, metabolic, and life-threating disorders. A leader in photomedicine and melanocortin science, Clinvuel's innovations address unmet needs in systemic photoprotection, DNA repair, and repigmentation for patients lacking effective treatment alternatives.

Market cap \$554.2M

12:00PM MICROBA LIFE SCIENCES (MAP)

Microba Life Sciences is a commercial-stage biotechnology company advancing microbiome testing and therapeutics to transform chronic disease diagnosis and treatment. Leveraging its properitary analysis platform and partnerships, including with Sonic Healthcare, Microba is rapidly expanding internationally to lead the emerging \$100 billion global microbiome diagnostics and therapeutics market.

Market cap \$45.1M



1:00PM NOVA EYE MEDICAL (EYE)

Nova Eye Medical develops and commercialises innovative ophthalmic treatment technologies for glaucoma and age-related eye diseases. The company's proprietary iTrackTM and Molteno3® devices are used globally by ophthalmologists to restore and preserve vision, providing effective minimally invasive options that address a leading cause of irreversible blindness.

Market cap \$38.5M

1:30PM ONEVIEW HEALTHCARE (ONE)

OneView Healthcare provides a cloud-based platform unifying hospital systems, content, and services at the point of care. Its technology empowers patients, streamlines workflows for care teams, and simplifies operations for executives. Partnering with major healthcare systems globally, OneView enhances engagement and efficiency across more than 80 hospitals worldwide.

Market cap \$172.2M

2:00PM AUSTCO HEALTHCARE (AHC)


Austco Healthcare is a global provider of innovative clinical communication solutions, including Tacera Workflow, Pulse Mobile, RTLS, and Patient Information Boards. In FY25, Austco delivered record revenue of \$81.4m (+40%) and EBITDA of \$13.0m (+62%), driven by strategic acquisitions, product innovation, and accelerating global market expansion.

Market cap \$161.1M

2:30PM TRAJAN (TRJ)

Trajan develops and manufactures analytical and lifescience instrumentation, consumables, and automation systems for biological, food, environmental and diagnostics workflows. The company serves global markets from sites across the US, Europe, Australia and Asia, and is scaling its disruptive technology portfolio.

Market cap \$111.4M



3:00PM ALCIDION (ALC)

Alcidion's platform, Miya Precision, leverages cutting edge technology to support better digitally enabled care that improves efficiencies in clinical decision making, with a focus of helping healthcare providers manage patient information, streamline clinical workflows, and make better informed decisions about patient care.

Market cap \$119.5M

3:30PM PHARMX TECHNOLOGIES (PHX)

PharmX Technologies is a company that sits at the heart of the pharmacy network, providing critical cloud-based infrastructure that connects pharmacies, wholesalers, suppliers, and government. Its Gateway, Portal, Data, and eCommerce solutions streamline inventory management and enable smarter decisions, processing over A\$20 billion in orders annually across 99% of ANZ pharmacies.

Market cap \$89.9M

4:00PM MACH7 TECHNOLOGIES (M7T)


Mach7 Technologies is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organisations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and robust diagnostic workflow applications.

Market cap \$72.8M

4:30PM PRO MEDICUS (PME)

Pro Medicus is a global healthcare informatics company delivering advanced medical imaging solutions through its Visage 7 platform. Offering RIS, PACS, AI, and e-health technologies, Pro Medicus enables ultra-fast, cloud-based image viewing and analysis for hospitals and imaging centres worldwide, enhancing diagnostic precision and clinical efficiency.

Market cap \$26.7B



8:30AM IMPEDIMED (IPD)

ImpediMed is a company that designs and manufactures medical technologies using bioimpedance spectroscopy (BIS) and digital health platforms for non-invasive monitoring of body fluid and composition. Its FDA-cleared SOZO system enables early detection and prevention of breast cancer-related lymphedema, supports weight management, and aids clinicians in monitoring heart failure patients.

Market cap \$73.2M

9:00AM LTR PHARMA (LTP)

LTR Pharma is a company advancing a proprietary intranasal platform with commercial traction in Australia and global growth plans. Its lead products, SPONTAN® and ROXUS®, treat erectile dysfunction in under 10 minutes, while the pipeline candidate, OROFLOW®, targets oesophageal motility disorders, addressing significant unmet medical needs.

Market cap \$52.9M

9:30AM MEDICAL DEVELOPMENTS (MVP)


Medical Developments is a leader in emergency pain management, best known for Penthrox ("The Green Whistle"), an inhaled analgesic used in over 30 countries including Australia, the UK, and France. The company also produces respiratory products supporting patients with asthma and chronic obstructive pulmonary disease (COPD).

Market cap \$66.5M

10:00AM BIOME (BIO)

Biome is a health science company focused on developing, manufacturing, and commercialising evidence-based biotherapeutic and nutraceutical solutions. Integrating research, clinical validation, and commercial expertise, Biome aims to advance gut and systemic health through innovation probiotic technologies, expanding its footprint across healthcare, pharmacy, and practitioner networks globally.

Market cap \$99.3M



10:30AM RADIOPHARM THERANOSTICS (RAD)

Radiopharm Theranostics is a clinical-stage biotechnology company developing first-in-class radiopharmaceuticals for both diagnostic imaging and therapeutic applications in oncology. The company is advancing a pipeline of antibody, nanobody, peptide and small-molecule platforms targeting cancers with high unmet medical need.

Market cap \$64.0M

11:00AM CYCLOPHARM (CYC)

Cyclopharm is an Australian radiopharmaceutical company specialising in Technegas, a functional lung imaging system used in respiratory and nuclear medicine. Distributed in 66 countries, Technegas assists diagnosis of pulmonary embolism, COPD, asthma, and lung cancer. Following FDA approval, Cyclopharm is expanding its commercial footprint in the United States.

Market cap \$70.0M

11:30AM CLARITY PHARMACEUTICALS (CU6)


Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

Market cap \$1.7B

12:00PM TELIX PHARMACEUTICALS (TLX)

Telix is a global leader in radiopharmaceuticals, and its theranostic pipeline aims to address unmet medical needs in urologic, neurologic, musculoskeletal, and hematologic oncology. Telix's lead product for prostate imaging has been approved in Australia, Brazil, Canada, Europe, and the U.S. Telix's second-generation prostate imaging product has also been approved in the U.S.

Market cap \$5.1B



1:00PM ACTINOGEN MEDICAL (ACW)

Actinogen is advancing a revolutionary oral therapeutic, Xanamem, through pivotal clinical trials to transform treatment for Alzheimer's disease and major depressive disorder. Its mission is to improve lives by targeting brain cortisol with precision and innovation. The Company is ASX-listed and has operations based in Australia and the US.

Market cap \$133.5M

1:30PM ALTERITY THERAPEUTICS (ATH)

Alterity Therapeutics is a late clinical-stage biotech company developing disease-modifying therapies for neurodegenerative disorders. Its lead asset, ATH434, targets Parkinsonian syndromes – notably Multiple System Atrophy (MSA) – and has secured U.S. Food and Drug Administration Fast track status.

Market cap \$97.9M

2:00PM AMPLIA THERAPEUTICS (ATX)


Amplia Therapeutics is developing the best-in-class small molecule FAK inhibitor for use in solid tumours. The Company has reported promising data from the ACCENT trial in pancreatic cancer. Additional data from this trial and a second trial in the US will be discussed, along with plans for follow-on studies.

Market cap \$66.7M

2:30PM IMUGENE (IMU)

Imugene is a clinical-stage immune-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Its pipeline includes allogeneic CAR T cell therapy, oncolytic viruses and B-cell vaccine platforms targeting both blood and solid tumours.

Market cap \$104.1M



3:00PM EBR SYSTEMS (EBR)

EBR Systems develops leadless implantable cardiac devices using its proprietary WiSE CRT System technology, enabling wireless left-ventricular endocardial pacing for heart-failure and rhythm management. The company is focused on transforming cardiac resynchronisation therapy by eliminating pacing leads and improving patient outcomes.

Market cap \$526.4M

3:30PM EMVISION MEDICAL DEVICES (EMV)

EMVision Medical Devices is an Australian medical technology company developing portable, non-invasive brain imaging devices. Using advanced electromagnetic imaging, EMV aims to transform the rapid diagnosis and treatment of stroke and other time-critical neurological conditions, enabling affordable, safe, and accessible neurodiagnostics at the point of care.

Market cap \$167.3M

4:00PM ANTERIS TECHNOLOGIES (AVR)


Anteris Technologies is a structural heat company developing and commercialising its biomimetic DurAVR transcatheter heart-valve system, designed to mimic a health aortic valve. The company is headquartered in Australia with a significant U.S. presence and is advancing regulatory and clinical milestones globally.

Market cap \$107.6M

4:30PM IMRICOR MEDICAL SYSTEMS (IMR)

Imricor Medical Systems develops and manufactures MRI-compatible cardiac ablation devices, including its Vision-MR line and Advantage-MR EP system. Headquartered in the United States and listed in Australia, the company's technology enables real-time MRI-guided catheter ablation for arrhythmias, aiming to improve outcomes and reduce costs.

Market cap \$447.7M



8:30AM SYNTARA (SNT)

Syntara is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. Lead candidate amsulostat is in phase 2 trials for the bone marrow cancer myelofibrosis.

Market cap \$47.3M

9:00AM IMMUTEP (IMM)

Immutep is a clinical-stage biotechnology company pioneering immunotherapies that modulate the immune system to fight cancer and autoimmune diseases. Its diversified pipelines includes four clinical-stage candidates, led by eftilagimod alfa (efti) for oncology and IMP761 for autoimmune disorders, targeting the LAG-3 immune checkpoint pathway.

Market cap \$390.1M


9:30AM IMMVIRX

ImmVirX is a clinical stage oncology company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.

10:00AM MESOBLAST (MSB)

Mesoblast is a global leader in developing allogeneic, off-the-shelf cellular medicines for severe inflammatory diseases. Its FDA-approved therapy RYONCIL (Remestemcel-L) treats paediatric SR-aGvHD, with further programs targeting adult Sr-aGvHd and inflammatory bowel disease. Rexlemestrocel-L is in development for heart failure and chronic low back pain.

Market cap \$3.0B



10:30AM SALUDA MEDICAL

Saluda Medical is a commercial-stage medical-device company pioneering a closed-loop neuromodulation platform. Its flagship Evoke System for spinal-cord stimulation senses and adjusts neural activity in real time to treat chronic pain. In the U.S., the company secured FDA approval for its automated programming platform.

11:00AM CYNATA THERAPEUTICS (CYP)

Cynata is a clinical-stage biotechnology company transforming regenerative medicine through the proprietary Cymerus™ platform technology. Results of a Phase 2 trial in acute graft versus host disease (GvHD) and a Phase 3 trial in osteoarthritis are expected during the current financial year - building on previous positive clinical data in GvHD and diabetic foot ulcers.

Market cap \$54.6M


11:30AM POLYACTIVA

PolyActiva is a clinical-stage biopharmaceutical company developing novel drug delivery solutions to improve outcomes for patients with ocular conditions. The company's lead asset, PA5108, is a biodegradable ocular implant that delivers sustained latanoprost prodrug (NCE) therapy to reduce intraocular pressure in glaucoma and ocular hypertension.

12:00PM ORTHOCELL (OCC)

Orthocell is a regenerative medicine company focused on regenerating mobility for patients. They develop products for the repair of a variety of bone, nerve and tendon injuries. Orthocell's portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Market cap \$299.3M



1:00PM PROTEOMICS (PIQ)

Proteomics is creating and commercialising tests at the forefront of predictive diagnostics and precision medicine, in diseases from diabetic kidney disease to oesophageal cancer and endometriosis. Our mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

Market cap \$55.7M

1:30PM VITRAFY LIFE SCIENCES (VFY)

Vitrafy Life Sciences has developed a proprietary range of smart cryopreservation hardware and its LifeChain cloud-based software platform to deliver a complete cryopreservation solution. Combining advanced technology with seamless integration, Vitrafy ensures the preservation and integrity of sensitive biological materials, optimising storage and handling across life sciences industries.

Market cap \$61.8M


2:00PM QBIOTICS

QBiotics is an Australian public unlisted life sciences company that specialises in the discovery and development of plant-derived small molecules to treat diseases of high unmet need. Their initial focus is oncology and wound healing. The lead asset, tigilanol tiglate, is currently in Phase IIa clinical trials, while EBC-1013 is in Phase I clinical trials.

2:30PM ARTRYA (AYA)

Artrya is a medical technology company developing Al-powered solutions to improve the detection and management of coronary artery disease. Its proprietary Salix software analyses coronary CT scans to identify key biomarkers, enabling faster, more accurate diagnosis. Artrya is advancing regulatory and commercial initiatives across global healthcare markets.

Market cap \$575.1M



3:00PM ONCOSIL MEDICAL (OSL)

OncoSil Medical is a medical device company specialising in radiation therapy for the treatment of locally advance unresectable pancreatic cancer. The OncoSil device delivers targeted radioactive microparticles directly into pancreatic tumours. The treatment aims to improve treatment outcomes and enhance patient quality of life through precision oncology.

Market cap \$24.5M

3:30PM PYC THERAPEUTICS (PYC)

PYC Therapeutics is a genetic medicine specialist developing a pipeline of RNA drugs for patients with severe unmet medical needs. The Company has 3 clinical-stage assets reading out on human efficacy within the next 12 months.

Market cap \$688.2M

4:00PM PARADIGM BIOPHARMACEUTICALS (PAR)


Paradigm Biopharmaceuticals (ASX:PAR) is advancing a global Phase 3 trial of injectable PPS for knee osteoarthritis, with an interim analysis expected mid-2026. Fully funded to this milestone, iPPS offers yearlong pain relief after one six-week course, strong safety data, FDA Fast-Track status, and potential disease-modifying benefits.

Market cap \$156.4M

4:30PM STARPHARMA (SPL)

Starpharma is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Market cap \$138.0M



Get in touch with your Bell Potter contact for conference access or call 1300 023 557.

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or quarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/ advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.